Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
FiercePharma9d
Lilly, Merck team with Purdue University to pioneer new drug production methods
Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...
Hosted on MSN1d
AI Pharma: 2 Paths to AI-Powered Drug Investment
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...
STAT19d
Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund
In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Swissinfo8d
DeepMind’s Hassabis Sees AI-Designed Drug Trials This Year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this ...
STAT13d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
Business Insider6d
Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances
Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising growth ... to positive developments in their drug pipeline, particularly the oral GLP-1 ...
The Motley Fool4d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing ... case for why this could be Lilly's next big opportunity. According to data compiled by Coherent Market Insights, the global oncology drug market is expected to ...
Investing5d
Eli Lilly stock dips on Novo Nordisk's rival drug data
On Friday, Novo Nordisk released promising trial results for its obesity treatment, amycretin, which showed a significant weight loss in participants, outpacing Eli Lilly's own drug in early ...